Clinical safety risks of the injections containing the pharmaceutical excipient dextran 40
10.3760/cma.j.cn114015-20230923-00702
- VernacularTitle:含药用辅料右旋糖酐40的注射剂临床用药安全风险
- Author:
Tai ZHANG
1
;
Qiang WU
;
Jin WANG
;
Yunli ZHANG
Author Information
1. 青岛大学附属妇女儿童医院药学部，青岛 266034
- Publication Type:Journal Article
- Keywords:
Injections;
Excipients;
Glucans;
Dextrans;
Dextran 40;
Medication safety
- From:
Adverse Drug Reactions Journal
2024;26(4):234-237
- CountryChina
- Language:Chinese
-
Abstract:
Dextran 40 is a commonly used pharmaceutical excipient and can be used as formulations of dry powder for injection. But it has antigenic properties that can trigger severe allergic reactions. Therefore, injections containing the excipient dextran 40 may have additional safety risks that are not easily recognized in the clinic. Dextran 40-associated allergic reactions may also interfere with the diagnosis of certain diseases and limit the choice of therapeutic drugs. Revision of the relevant instructions and improvement of the clinical dosing process can help reduce the risk of injections containing the excipient dextran 40 in clinical use. Physicians and pharmacists should expand their clinical and pharmacological thinking to evaluate the antigenicity of the excipient dextran 40 as an independent influence factor in the rational and safe use of medication. Identification individual cases of adverse events caused by this excipient and taking measures to minimize adverse events caused by this excipient in different drugs can help effectively reduce the risk of drug safety of the relevant formulations.
